Pfizer Saudi Arabia has signed a Memorandum of Understanding (MoU) with Lifera, a company owned by Saudi Arabia’s Public Investment Fund (PIF), to explore local drug manufacturing and technology transfer opportunities in the Kingdom.
Announced during the Global Health Exhibition 2025 in Riyadh, the agreement supports Vision 2030 goals to build a self-sufficient biopharmaceutical industry and strengthen national pharmaceutical security.
The partnership aims to enhance local production, workforce development, and supply chain resilience, reducing reliance on imports and advancing Saudi Arabia’s research and manufacturing capabilities.
Nick Lagunowich, Pfizer’s President of Emerging Markets, said the collaboration underscores Pfizer’s “long-term commitment to Saudi Arabia’s healthcare development,” while Dr. Mohamed Fawzy, Country Manager of Pfizer Saudi Arabia, highlighted its role in “advancing pharmaceutical security and technology localization.”
Lifera, launched by the PIF to drive national biopharma growth, plays a central role in expanding vaccine and biologics production. The initiative is expected to boost innovation, create high-value jobs, and position the Kingdom as a regional life sciences hub.
